Lunai Bioworks (LNAI) Financials
Ticker history: RENB became LNAI (Lunai Bioworks Inc) on . Earlier news and filings retain their original names and dates. View RENB history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Oct 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LNAI SEC filings page.
Lunai Bioworks Inc (LNAI) reported $52K in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lunai operates at a tiny revenue base while financing a much larger cost structure through external funding.
In FY2026, operating cash flow was negative$5.3M even though capital spending was only$1K , so the cash problem is operating scale rather than heavy reinvestment. Financing provided$6.4M while investing contributed$543K , indicating reported cash needs were met primarily outside operations.
The latest period pairs just
The balance sheet remains strained: current liabilities were
Financial Health Signals
Lunai Bioworks Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Lunai Bioworks Inc scores -77.28, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $514.0M against total assets of $9.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Lunai Bioworks Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.
Lunai Bioworks Inc reported a net loss of $3.6M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Lunai Bioworks Inc reported an operating loss of $8.7M against $235K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Lunai Bioworks Inc reported a net loss of $2.0M in Q4 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
Lunai Bioworks Inc recorded an outflow of $1.8M in free cash flow in Q4 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Lunai Bioworks Inc held $1.7M in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
Lunai Bioworks Inc reported no capital expenditure in Q4 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
LNAI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $21K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $21K | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $16K | $46K-71.5% | $24K-93.7% | N/A | N/A | $161K-74.0% | $390K-31.1% |
| SG&A Expenses | $2.2M | $1.4M-66.4% | $1.8M-59.4% | $2.4M-54.5% | N/A | $4.2M-44.8% | $4.4M+20.4% | $5.3M-36.1% |
| Operating Income | N/A | -$1.5Mn/m | -$1.8Mn/m | -$3.3Mn/m | N/A | -$4.2Mn/m | -$4.5Mn/m | -$53.3Mn/m |
| EBITDA | N/A | -$1.5Mn/m | -$1.8Mn/m | -$3.3Mn/m | N/A | -$4.1Mn/m | -$4.5Mn/m | -$53.3Mn/m |
| Interest Expense | N/A | $108K-42.7% | $122K+22.9% | $122K-51.1% | N/A | $189K-37.9% | $99K-64.0% | $250K+39.5% |
| Net Income | -$2.0M | -$2.6M-1459.3% | -$1.8Mn/m | $2.8Mn/m | N/A | $189Kn/m | -$7.3Mn/m | -$44.2Mn/m |
| EPS (Basic) | N/A | -$0.10 | -$0.08 | $0.13 | -$0.76n/m | $0.00 | -$0.45 | -$2.76 |
| EPS (Diluted) | N/A | -$0.10 | -$0.08 | $0.13 | -$0.76n/m | $0.00 | -$0.45 | -$2.76 |
| Diluted Shares (Avg) | N/A | 25M | 23M | 23M | N/A | 16M | 16M | 16M |
Not reported in any period shown, so not listed: Cost of Revenue, Income Tax.
LNAI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.9M+20.8% | $9.9M-91.6% | $6.7M-94.0% | $7.0M-94.3% | $8.2M-95.0% | $117.7M-33.9% | $111.3M+91.9% | $121.8M+111.7% |
| Current Assets | $2.0M+94.6% | $3.7M+1.8% | $514K-69.9% | $800K-58.9% | $1.0M-47.6% | $3.7M+200.7% | $1.7M-28.9% | $1.9M+2.2% |
| Cash & Equivalents | $1.7M+1748.6% | $3.2M+241.8% | $492K+57.7% | $625K+183.3% | $93K-58.0% | $923K+195.2% | $312K+27.8% | $221K-57.9% |
| Short-Term Investments | $0 | $0 | $0n/m | $0n/m | N/A | N/A | $0n/m | $0n/m |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $964K | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0n/m | $0n/m | N/A | N/A | $0n/m | $0n/m |
| Goodwill | $6.0M0.0% | $6.0M-94.7% | $6.0M-94.5% | $6.0M-95.0% | $6.0M-96.3% | $112.6M-31.4% | $108.0M+827.8% | $118.2M+915.2% |
| Total Liabilities | $19.0M-35.9% | $19.4M-33.8% | $20.2M-31.0% | $20.0M-15.8% | $29.6M-5.0% | $29.3M-32.8% | $29.3M+103.0% | $23.7M+119.5% |
| Current Liabilities | $18.9M-35.1% | $19.3M-33.1% | $20.0M-30.1% | $19.7M-14.4% | $29.2M-3.8% | $28.8M+38.2% | $28.6M+107.9% | $23.0M+128.2% |
| Non-Current Liabilities | $56K-86.8% | $131K-73.6% | $214K-68.3% | $279K-60.7% | $425K-49.6% | $498K-97.8% | $674K+1.5% | $710K-1.5% |
| Long-Term Debt | N/A | N/A | $978K | $938K | $16.1M | N/A | N/A | N/A |
| Total Equity | -$9.0Mn/m | -$9.6M-110.8% | -$13.5M-116.5% | -$13.0M-113.3% | -$21.3M-116.2% | $88.4M-34.2% | $82.1M+88.2% | $98.1M+109.8% |
| Retained Earnings | -$514.0Mn/m | -$512.0Mn/m | -$509.4Mn/m | -$507.6Mn/m | -$510.5Mn/m | -$383.7Mn/m | -$383.9Mn/m | -$376.7Mn/m |
Not reported in any period shown, so not listed: Inventory.
LNAI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.8Mn/m | -$1.0Mn/m | -$1.1Mn/m | -$1.3Mn/m | -$1.8Mn/m | -$1.5Mn/m | -$2.6Mn/m | -$2.0Mn/m |
| Depreciation & Amortization | $30K-22.7% | $11K-65.6% | $11K-64.7% | $42K+28.2% | $38K+23.2% | $32K+5.5% | $32K-3.2% | $32K+18.8% |
| Stock-Based Compensation | N/A | $169K-88.7% | $129K-76.9% | $181K-49.3% | N/A | $1.5M-19.5% | $559K-44.1% | $358K-63.6% |
| Capital Expenditures | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$1.8M | -$1.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0-100.0% | $0 | -$1K | $545Kn/m | $964Kn/m | N/A | N/A | $0n/m |
| Financing Cash Flow | $395K+121.2% | $3.7M+3.3% | $950K-63.3% | $1.3M-33.8% | $178K-92.8% | $3.6M+35.7% | $2.6M-9.0% | $2.0M-20.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
LNAI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -7054.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -12278.6% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | 0.2%+44.1pp | -8.8%+1.6pp | -45.1%-25.4pp |
| Return on Assets | -20.2% | -26.1%-26.2pp | -27.0%-20.5pp | 40.5%+76.8pp | N/A | 0.2%+33.3pp | -6.5%+1.3pp | -36.3%-20.4pp |
| Current Ratio | 0.11+0.1x | 0.19+0.1x | 0.030.0x | 0.040.0x | 0.040.0x | 0.13+0.1x | 0.06-0.1x | 0.08-0.1x |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | 0.330.0x | 0.360.0x | 0.240.0x |
| Asset Turnover | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | -4903.3% | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$9.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.11), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Lunai Bioworks Inc LNAI | FY2026 | $52K | -$3.6M | N/A | $830K | — |
| CDT Equity Inc. CDT | FY2025 | N/A | N/A | N/A | $634K | — |
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $1.2M | 54/100 |
| Artelo Biosciences, Inc. ARTL | FY2025 | N/A | -$12.9M | N/A | $1.2M | — |
| Bone Biologics Corp BBLG | FY2025 | N/A | -$3.1M | N/A | $1.3M | — |
Where Lunai Bioworks Inc Ranks
Frequently Asked Questions
Lunai Bioworks Inc (LNAI) reported $52K in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Lunai Bioworks Inc (LNAI) reported a net loss of $3.6M in fiscal year 2026.
Lunai Bioworks Inc (LNAI) had EBITDA of -$8.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Lunai Bioworks Inc (LNAI) recorded an outflow of $5.3M in free cash flow during fiscal year 2026. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Lunai Bioworks Inc (LNAI) recorded an outflow of $5.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Lunai Bioworks Inc (LNAI) had $9.9M in total assets as of fiscal year 2026, including both current and long-term assets.
Lunai Bioworks Inc (LNAI) invested $1K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
Lunai Bioworks Inc (LNAI) invested $25K in research and development during fiscal year 2026.
Lunai Bioworks Inc (LNAI) had a current ratio of 0.11 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
Lunai Bioworks Inc (LNAI) had a return on assets of -35.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Lunai Bioworks Inc (LNAI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $830K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Lunai Bioworks Inc (LNAI) trades at 16.0x sales, its market capitalization divided by $52K revenue, FY2026. The market capitalization is $830K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2026, Lunai Bioworks Inc (LNAI) held $1.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.3M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Lunai Bioworks Inc (LNAI) has negative shareholder equity of -$9.0M as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Lunai Bioworks Inc (LNAI) has an Altman Z-Score of -77.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Lunai Bioworks Inc (LNAI) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Lunai Bioworks Inc (LNAI) reported a net loss of $3.6M while operations used $5.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Lunai Bioworks Inc (LNAI) reported an operating loss of $8.7M against $235K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.